Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Sci Rep ; 11(1): 18008, 2021 09 09.
Article in English | MEDLINE | ID: mdl-34504192

ABSTRACT

The programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) pathway could affect antimicrobial immune responses by suppressing T cell activity. Several recent studies demonstrated that blocking of the PD-1/PD-L1 pathway exacerbated Mycobacterium tuberculosis infection. However, the effect of blocking this pathway in pulmonary Mycobacterium avium-intracellulare complex (MAC) infection is not fully understood. Wild-type, PD-1-deficient mice, and PD-L1-deficient mice were intranasally infected with Mycobacterium avium bacteria. Depletion of PD-1 or PD-L1 did not affect mortality and bacterial burden in MAC-infected mice. However, marked infiltration of CD8-positive T lymphocytes was observed in the lungs of PD-1 and PD-L1-deficient mice compared to wild-type mice. Comprehensive transcriptome analysis showed that levels of gene expressions related to Th1 immunity did not differ according to the genotypes. However, genes related to the activity of CD8-positive T cells and related chemokine activity were upregulated in the infected lungs of PD-1 and PD-L1-deficient mice. Thus, the lack of change in susceptibility to MAC infection in PD-1 and PD-L1-deficient mice might be explained by the absence of obvious changes in the Th1 immune response. Furthermore, activated CD8-positive cells in response to MAC infection in these mice seemed to not be relevant in the control of MAC infection.


Subject(s)
B7-H1 Antigen/genetics , CD8-Positive T-Lymphocytes/immunology , Mycobacterium avium/immunology , Programmed Cell Death 1 Receptor/genetics , Th1 Cells/immunology , Tuberculosis/genetics , Animals , B7-H1 Antigen/deficiency , B7-H1 Antigen/immunology , CD8-Positive T-Lymphocytes/microbiology , Cell Movement , Female , Gene Expression Profiling , Gene Expression Regulation , Genotype , Lung/immunology , Lung/microbiology , Lung/pathology , Lymphocyte Activation , Mice , Mice, Knockout , Mycobacterium avium/pathogenicity , Programmed Cell Death 1 Receptor/deficiency , Programmed Cell Death 1 Receptor/immunology , Survival Analysis , Th1 Cells/microbiology , Transcriptome , Tuberculosis/immunology , Tuberculosis/microbiology , Tuberculosis/mortality
3.
Front Immunol ; 12: 770305, 2021.
Article in English | MEDLINE | ID: mdl-35069543

ABSTRACT

HAS2 is a member of the gene family encoding the hyaluronan synthase 2, which can generate high-molecular-weight hyaluronan (HMW-HA). Our previous study identified HAS2 as a candidate gene for increased susceptibility to adult asthma. However, whether HAS2 dysfunction affects airway remodeling and steroid insensitivity is still limited. Therefore, this study aimed to clarify the Has2 dysfunction, triggering severe airway remodeling and steroid insensitivity in a murine model of asthma. Has2 heterozygous-deficient (Has2+/-) mice and their wild-type littermates have been evaluated in a model of chronic ovalbumin (OVA) sensitization and challenge. Mice present a higher sensitivity to OVA and higher IL-17 release as well as eosinophilic infiltration. RNA sequencing demonstrated the downregulation of EIF2 signaling pathways, TGF-ß signaling pathways, and heat shock proteins with Th17 bias in Has2+/--OVA mice. The combined treatment with anti-IL-17A antibody and dexamethasone reduces steroid insensitivity in Has2+/--OVA mice. Has2 attenuation worsens eosinophilic airway inflammation, airway remodeling, and steroid insensitivity. These data highlight that HAS2 and HMW-HA are important for controlling intractable eosinophilic airway inflammation and remodeling and could potentially be exploited for their therapeutic benefits in patients with asthma.


Subject(s)
Airway Remodeling/immunology , Asthma/immunology , Drug Resistance/immunology , Hyaluronan Synthases/immunology , Airway Remodeling/drug effects , Airway Remodeling/genetics , Animals , Asthma/chemically induced , Asthma/genetics , Drug Resistance/genetics , Hyaluronan Synthases/genetics , Mice , Mice, Knockout , Ovalbumin/toxicity , Steroids/pharmacology
4.
High Alt Med Biol ; 21(4): 406-408, 2020 12.
Article in English | MEDLINE | ID: mdl-33179963

ABSTRACT

Sherpa, Mingma Thsering, and Raksha Shrestha. Stroke at high altitude in an experienced Sherpa climber: A case report. High Alt Med Biol. 21:406-408, 2020.-A 44-year-old experienced Sherpa climber had dizziness with nausea and several episodes of vomiting while at Camp 2 of Mount Everest (6400 m). He was airlifted from Everest Base Camp to Kathmandu for further treatment. Neurological assessment revealed cerebellar signs with ataxia. Sensory examination revealed hypoesthesia on the extremities of the left side and right half of the face. Laboratory workup revealed increased hemoglobin and hematocrit levels. Magnetic resonance imaging of brain revealed ischemic infarction of right cerebellar hemisphere in the right posterior inferior cerebellar artery territory extending to medulla. Patient was managed with aspirin, supportive measures, and physiotherapy, and made a complete recovery after 2 months. This is the first documented case of ischemic stroke in a healthy experienced Sherpa climber. Although the exact cause of stroke in our patient remains uncertain, the prothrombotic state due to high altitude compounded by impaired cerebral autoregulation and dehydration may have been contributory factors.


Subject(s)
Altitude , Stroke , Adult , Brain , Homeostasis , Humans , Male , Stroke/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...